Attached files
| file | filename |
|---|---|
| EX-32.1 - EX-32.1 - INVIVO THERAPEUTICS HOLDINGS CORP. | nviv-20170630ex32150aec7.htm |
| EX-31.2 - EX-31.2 - INVIVO THERAPEUTICS HOLDINGS CORP. | nviv-20170630ex312b874ac.htm |
| EX-31.1 - EX-31.1 - INVIVO THERAPEUTICS HOLDINGS CORP. | nviv-20170630ex311fb1736.htm |
| EX-10.1 - EX-10.1 - INVIVO THERAPEUTICS HOLDINGS CORP. | nviv-20170630ex101da601c.htm |
| 10-Q - 10-Q - INVIVO THERAPEUTICS HOLDINGS CORP. | nviv-20170630x10q.htm |
Exhibit 32.2
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report on Form 10-Q of InVivo Therapeutics Holdings Corp. (the “Company”) for the quarter ended June 30, 2017, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Christopher McNulty, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
|
(1) |
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
|
(2) |
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.
|
Date: August 8, 2017 |
/s/ Christopher McNulty |
|
|
Christopher McNulty |
|
|
Chief Financial Officer (Principal Financial and Accounting Officer) |